PR antagonist immunotherapy vs metastatic colon cancer

[Guest guest]

I know that this may be anathema for those on this list who consider

mifepristone (RU-486) to be the spawn of Satan, but I hope you

seriously consider the mechanism of action and possible natural alternatives.

------------------------

Anticancer Res. 2009

May;29(5):1611-3.<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051 & i\

tool=AbstractPlus-def & uid=19443374 & nlmid=8102988 & db=pubmed & url=http://ar.iiarjou\

rnals.org/cgi/pmidlookup?view=long & pmid=19443374>

Click here to read

Links

Mifepristone may halt progression of extensively metastatic human

adenocarcinoma of the colon - case report.

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Check%20J\

H%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_D\

iscoveryPanel.Pubmed_RVAbstractPlus>Check

JH,

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Dix%20E%2\

2%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_Disc\

overyPanel.Pubmed_RVAbstractPlus>Dix

E,

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Sansoucie\

%20L%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubme\

d_DiscoveryPanel.Pubmed_RVAbstractPlus>Sansoucie

L,

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Check%20D\

%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_Di\

scoveryPanel.Pubmed_RVAbstractPlus>Check

D.

Department of Obstetrics and Gynecology, Division of Reproductive

Endocrinology and Infertility, The University of Medicine and

Dentistry of New Jersey, NJ, U.S.A.

BACKGROUND: Mifepristone, a progesterone receptor antagonist has been

found to improve the length and quality of life in various

spontaneous murine cancer models including tumors without

progesterone receptors theoretically by inhibiting an

immunomodulatory protein that suppresses natural killer cell function

in the tumor microenvironment. MATERIALS AND METHODS: Mifepristone

200 mg per day by mouth was given to two patients with stage 4 colon

cancer with extensive metastases. RESULTS: Both patients not only

survived far longer than expected but had marked improvement in their

quality of life similar to mice. Though the metastatic lesions did

not disappear, no new ones appeared for a long time and the ones

present did not grow. The drug was extremely well tolerated.

CONCLUSION: The use of progesterone receptor antagonists may present

a novel immunotherapy to help fight cancer. A larger controlled study

is needed.